HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

484.542

-12.216-2.46%

Number of Gainers:7

Number of Losers:24

Number of Flat:2

PE:- -

High:496.758

Open:496.758

Low:480.418

Close:496.758

Volume:54.87M

Turnover:1.32B

Market Cap:307.49B

Float Cap:274.19B

Loading ...

EVEREST MED's pioneering cardiovascular treatment receives green light in China, introducing the first and only on-demand rescue therapy for adults with PSVT

AH Premium Rankings Update: September 3 Market Close

Yinchuan Market Regulators Roll Out Comprehensive Measures to Implement Revised Medical Device Production Quality Standards

HK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira

Keymed Biosciences Climbs on Licensing Deal with Aeira Pte

Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support

Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets

Is CStone Pharmaceuticals (SEHK:2616) Fully Valued On Interim Results And CS2009 Progress?

Simply Wall St.

Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study

THOMSON REUTERS

We Might See A Profit From Venus Medtech (Hangzhou) Inc. (HKG:2500) Soon

Simply Wall St.

Akeso Says Ivonescimab Meets Overall Survival Endpoint in Phase III HARMONi-2 Lung Cancer Trial

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line Pd-L1-Positive Nsclc

THOMSON REUTERS

Akeso - Ivonescimab Demonstrates Statistically Significant Improvement over Pembrolizumab

THOMSON REUTERS

HBM Holdings Clarifies Reasons Behind Executive Director's Departure

Alphamab Oncology Files HKEX Next-Day Disclosure Return for Share Buyback at HKD 8.57

CanSino Biologics' Global Revenue Soars 4,724% in First Half, Systemic Expansion Strategy Unlocks Growth Potential

Keymed Biosciences Licenses Stapokibart Marketing, Sales Rights in 18 Southeast and Central Asia Markets to Aeira

KeyMed Biosciences - Aeira Responsible for Registration and Commercialization of Stapokibart Injection in 18 Countries and Regions

THOMSON REUTERS

KeyMed Biosciences - Enters Exclusive Licensing Agreement with Aeira Pte for Stapokibart Injection

THOMSON REUTERS

OCUMENSION-B Completes Patient Enrollment in Phase III Trial of Dry Eye Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/BK1574/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":484.54214,"timestamp":1789098757924,"preClose":496.75812,"halted":0,"volume":54874261,"delay":0,"changeRate":-0.024591,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-12.215973,"latestTime":"09-11 11:52:39","open":496.75812,"high":496.75812,"low":480.41833,"amount":1316904895,"amplitude":0.032893,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1789099200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.703217,"peRate":164.740195,"turnoverRate":0.002088,"increases":7,"decrements":24,"flats":1,"marketCap":307487330800,"floatMarketCap":274194583688},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.032893,"preClose":496.75812,"low":480.41833,"pbRate":"3.703217","latestPrice":484.54214,"volume":54874261,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.002088,"peRate":164.740195,"marketCap":307487330800,"floatMarketCap":274194583688,"timestamp":1789098757924,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":24,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1152809628","title":"EVEREST MED's pioneering cardiovascular treatment receives green light in China, introducing the first and only on-demand rescue therapy for adults with PSVT","url":"https://stock-news.laohu8.com/highlight/detail?id=1152809628","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152809628?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:50","pubTimestamp":1788425447,"startTime":"0","endTime":"0","summary":"On September 3rd, Hong Kong-listed innovative drug developer EVEREST MED (01952) announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","HRTS","01952","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199507474","title":"AH Premium Rankings Update: September 3 Market Close","url":"https://stock-news.laohu8.com/highlight/detail?id=1199507474","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199507474?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:22","pubTimestamp":1788423720,"startTime":"0","endTime":"0","summary":"As of the close on September 3, NE ELECTRIC (00042), ZHEJIANG SHIBAO (01057), and HOLLY FUTURES (03678) occupy the top three positions in the AH premium rate rankings, with premium rates of 993.12%,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","LU1152091168.USD","LU1008478684.HKD","LU0052750758.USD","LU0329678170.USD","03143","SG9999011746.SGD","LU0348788117.USD","02692","LU2008162690.USD","BK1594","LU1188198961.HKD","LU0287142896.SGD","LU0431992006.USD","BK1506","BK1562","IE00B3M56506.USD","LU1242518931.SGD","03328","LU1481107354.HKD","399300","LU2097828714.EUR","LU0181495838.USD","LU1282648689.USD","LU2097828557.USD","BK1191","BK1544","LU0828237510.HKD","BK1183","IE00B29SXG58.USD","IE0032431581.USD","IE00B031J352.USD","LU0072913022.USD","LU1880383440.USD","LU0449509016.USD","LU0328353924.USD","LU1720050803.USD","LU0823426480.USD","LU0051755006.USD","03968","LU0228367735.SGD","BK1592","LU1115378108.SGD","00991","LU0862451753.SGD","LU1251922891.USD","LU1993786604.SGD","LU0315179316.USD","LU0345780521.USD","LU1152091754.HKD","LU0348825331.USD","LU0229945570.USD","IE00BVYPNQ40.USD","02218","BK1144","02899","LU1226287529.USD","LU0488056044.USD","LU0821914370.USD","LU0163747925.USD","HK0000352291.HKD","LU1831875114.USD","BK1231","BK1574","LU0210526637.USD","IE00B031HY20.USD","BK1214","BK1564","BK1122","LU1675838814.USD","LU0117841782.USD","00300","LU0737861772.HKD","LU1282649067.USD","LU2294711473.HKD","LU0540923850.HKD","LU0329678337.USD","LU1366334578.USD","LU0320764755.SGD","BK1522","BK1554","LU1244550494.USD","LU0828237940.HKD","LU1328277881.USD","LU1282649810.SGD","IE00BF5LJ272.USD","BK1161","82846","BK1514","LU0708995583.HKD","LU0359201612.USD","LU1770034418.SGD","LU0531970944.HKD","LU1961090484.USD","LU0266512473.USD","LU1813983027.USD","LU1282649141.HKD","BK1546","LU0868486357.SGD","LU0543330566.HKD","03308","LU0572944931.SGD","SG9999002463.SGD","LU1064131342.USD","LU0254981946.USD","01812","LU0348805143.USD","LU1224709979.USD","LU1960683339.HKD","LU0593848301.USD","LU0106959298.USD","BK1125","SG9999004220.SGD","LU0307460666.USD","00042","LU0128522157.USD","LU1366334651.USD","LU0149534421.HKD","BK1135","LU0370786039.SGD","LU0348735423.USD","83188","LU0326950275.SGD","BK1593","IE00B0169L03.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0469268626.HKD","LU0543330483.HKD","159982","LU2039709279.SGD","SG9999006597.SGD","02701","LU0502904849.HKD","LU0173614495.USD","LU0791591158.USD","LU1794554557.SGD","LU2476274308.USD","02359","LU1242518857.USD","BK1237","LU0314109678.HKD","LU0456854461.SGD","LU0918141887.USD","LU0791590937.USD","02009","06869","LU0269904917.USD","LU2226246903.HKD","BK1560","LU2399975544.HKD","LU1769817096.USD","06185","SG9999002828.SGD","LU0531971595.HKD","HK0000352382.USD","IE00BGHQDM52.EUR","LU0979878070.USD","LU1211504680.USD","02691","LU0456846285.SGD","LU0348827113.USD","LU0516422952.EUR","LU1504937902.USD","LU0165289439.USD","BK1141","LU0463099449.HKD","EWH","00553","01349","LU2394011477.USD","BK1181","SG9999014674.SGD","LU0797268264.HKD","LU0082770016.USD","06826","LU0359202008.SGD","LU2125910500.SGD","00811","LU0516422366.SGD","LU0516422440.USD","SG9999001226.SGD","LU2242644610.SGD","LU0588546209.SGD","BK1223","LU0048580855.USD","BK1190","HK0000306685.HKD","HK0001040143.USD","07233","LU0164865239.USD","BK1530","IE00BZ08YS42.EUR","LU0348814723.USD","LU1303224171.USD","LU1105468828.SGD","LU0029875118.USD","LU3063872942.SGD","BK1147","LU1688375341.USD","LU0266512127.USD","LU0345780281.USD","LU0589944569.HKD","LU0871576103.HKD","LU1807302812.USD","BK1105","LU0417516902.SGD","LU0244354667.USD","BK1503","03268","BK1130","IE00BMCWC346.EUR","LU0561508036.HKD","IE00BZ08YT58.USD","LU2097828631.EUR","LU0348767384.USD","06745","LU0214875030.USD","BK1149","LU1244550221.USD","LU1048596156.SGD","LU1655091616.SGD","LU0607220059.USD","LU2097828474.EUR","03759","LU1023057109.AUD","LU2264538146.SGD","BK1523","IE0031814852.USD","LU0880133367.SGD","01108","LU2476274720.SGD","BK1551","LU0634319403.HKD","LU0456827905.SGD","BK1610","LU1808992512.USD","LU1880383366.USD","BK1563","IE00BVYPNP33.GBP","BK1163","LU1046422090.SGD","BK1521","HK0000320264.USD","LU0417516738.SGD","LU0140636845.USD","00187","LU0231483743.USD","BK1170","LU0348766576.USD","BK1116","BK1583","LU0737861699.HKD","SG9999001093.SGD","LU0516423091.SGD","BK1171","HK0000320223.HKD","LU0648948544.HKD","LU0106252389.USD","HK0000306701.USD","LU0164939612.USD","03188","06821","LU0359201885.HKD","LU0509642566.USD","BK1507","LU0455707207.USD","LU0228659784.USD","LU0149721374.USD","LU1719994722.HKD","02338","01057","BK1505","BK1198","LU2778985437.USD","LU0620787316.HKD","LU0164880469.USD","LU0039217434.USD","LU1244550577.SGD","LU0348816934.USD","LU0890818403.SGD","IE00BZ08YR35.GBP","LU0320764599.SGD","LU0384037296.USD","LU0096374516.USD","LU1255011170.USD","LU0211977185.USD","LU0918141705.HKD","BK1533","LU2045819591.USD","BK1202","LU2097828805.USD","LU2177674079.SGD","03986","LU0501845795.SGD","LU0067412154.USD","LU1769817179.HKD","BK1249","03130","LU0049853897.USD","02827","02475","HK0001040168.HKD","01877","83130","LU1988902786.USD","LU0828238088.HKD","03678","LU0823426308.USD","LU0061477393.USD","LU0516423174.USD","BK1110","BK1515","IE0034224299.USD","IE00BYV24P56.USD","LU0672654166.SGD","IE0008368742.USD","LU0043850808.USD","01033","LU0327786744.USD","00568","LU0886674414.USD","03750","IE0008369823.USD","LU0082770016.SGD","02846","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121486923","title":"Yinchuan Market Regulators Roll Out Comprehensive Measures to Implement Revised Medical Device Production Quality Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=1121486923","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121486923?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:00","pubTimestamp":1788422444,"startTime":"0","endTime":"0","summary":"The Yinchuan Municipal Market Supervision Administration in Ningxia is advancing a multi-pronged strategy to ensure the smooth implementation of the newly revised Medical Device Production Quality...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","HART","RSPH","159883","AGNG","BK1574","GDOC","MEDX","MDEV","LGHT","BK1100","09996","LNGR","PTH","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128255768","title":"HK Stock Alert: Keymed Bio Surges Over 3% on Landmark Licensing Deal with Aeira","url":"https://stock-news.laohu8.com/highlight/detail?id=1128255768","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128255768?lang=en_us&edition=fundamental","pubTime":"2026-09-03 14:18","pubTimestamp":1788416295,"startTime":"0","endTime":"0","summary":"Shares of KEYMED BIO-B (02162) climbed more than 3% in Hong Kong trading, last up 2.83% at HK$79.95 with turnover reaching HK$70.71 million. The rally follows the company's announcement of an...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02162","BK1161","BK4588","KCAI","BK1583","BK1587","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664826668","title":"Keymed Biosciences Climbs on Licensing Deal with Aeira Pte","url":"https://stock-news.laohu8.com/highlight/detail?id=2664826668","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664826668?lang=en_us&edition=fundamental","pubTime":"2026-09-03 12:31","pubTimestamp":1788409914,"startTime":"0","endTime":"0","summary":"BUZZ-Keymed Biosciences climbs on licensing deal with Aeira Pte** Shares of Keymed Biosciences Inc2162.HKclimb 2.9% in the third straight rising session to HK$80, their highest level since August 27** Keymed says it entered into an exclusive licensing agreement with pharmaceutical firm Aeira Pte, on marketing registration and commercialization of Stapokibart injection - an antibody drug for treatment of topic dermatitis, in 18 countries and regions including Southeast and Central Asia** Keymed says it will receive an upfront payment, milestone payments and commercialization milestone payments and it is entitled to receive royalties of up to a high double-digit percentage based on product net sales in the licensed territory** YTD, stock up 46.7%, Hang Seng Biotech Index.HSBIOup 10.6%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL1N44V04C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","02162","BK1161","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128427781","title":"Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support","url":"https://stock-news.laohu8.com/highlight/detail?id=1128427781","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128427781?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:00","pubTimestamp":1788404450,"startTime":"0","endTime":"0","summary":"Hong Kong-listed innovative drug stocks continued their upward momentum on September 3rd, with leading biotech names pushing the sector higher. CSPC Pharma and Sino Biopharmaceutical both advanced...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU1152091168.USD","BK1515","LU0326950275.SGD","LU1152091754.HKD","LU1226287792.SGD","159992","LU1226287875.USD","LU0072913022.USD","LU1813983027.USD","LU1960683339.HKD","LU1226288253.USD","LU1226288170.HKD","LU0067412154.USD","06978","BK1521","520880","IBBQ","LU0140636845.USD","LU0501845795.SGD","IE00BZ08YR35.GBP","LU1226287529.USD","MEDX","LU0314109678.HKD","LU1328277881.USD","IE00BZ08YS42.EUR","LNGR","FLHK","HK0000165453.HKD","IE0008369823.USD","KURE","159316","IE00B543WZ88.USD","LU0315179316.USD","BK1574","LU1008478684.HKD","LU1951186391.HKD","LU1993786604.SGD","IE00B5MMRT66.SGD","01093","LU2039709279.SGD","LU0880133367.SGD","BK1161","IE00B031HY20.USD","IE0008368742.USD","IE00BZ08YT58.USD","LU1807302812.USD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664582856","title":"Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2664582856","media":"MT Newswires","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664582856?lang=en_us&edition=fundamental","pubTime":"2026-09-03 09:42","pubTimestamp":1788399758,"startTime":"0","endTime":"0","summary":"Keymed Biosciences  has signed a licensing agreement with Singapore-based Aeira to market and sell Kangyueda in 18 markets across Central and Southeast Asia, according to a Wednesday bourse filing.Kangyueda is approved to treat moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyposis and seasonal allergic rhinitis, the filing said.Under the deal, Keymed will receive an upfront payment, milestone payments upon hitting certain targets and royalties in the high-double-digit percentage range based on regional sales.Aeira will be responsible for regulatory filings and the commercialization of Kangyueda in markets including Singapore, Malaysia, the Philippines, Thailand, Kazakhstan and Uzbekistan, as well as Hong Kong and Macau.Keymed will oversee the production and timely supply of Kangyueda to Aeira.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b010cf239ffd4765bcd3edd8f767f746","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1587","02162","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664828727","title":"Is CStone Pharmaceuticals (SEHK:2616) Fully Valued On Interim Results And CS2009 Progress?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664828727","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664828727?lang=en_us&edition=fundamental","pubTime":"2026-09-03 08:38","pubTimestamp":1788395893,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals (SEHK:2616) stock is in focus after the company released its 2026 interim update, highlighting fresh CS2009 clinical data, stronger pralsetinib uptake, and progress toward global Phase III trials.\nAt a latest share price of HK$6.18, CStone Pharmaceuticals has seen a 1 month share price return of 42.07% and a 90 day share price return of 23.35%. However, the 1 year total shareholder return declined 48.93%, which hints that recent clinical and interim results have...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/is-cstone-pharmaceuticals-sehk2616-fully-valued-on-interim-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2616/cstone-pharmaceuticals-shares/news/is-cstone-pharmaceuticals-sehk2616-fully-valued-on-interim-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","LU2065732104.USD","DCF","BK4097","PRGS","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664440588","title":"Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664440588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664440588?lang=en_us&edition=fundamental","pubTime":"2026-09-03 07:02","pubTimestamp":1788390131,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U147:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348767384.USD","LU0348827113.USD","LU0348783233.USD","LU0540923850.HKD","LU1720050803.USD","LU0348766576.USD","09926","IE00BPRC5H50.USD","LU0348735423.USD","LU2476274308.USD","LU0634319403.HKD","LU1794554557.SGD","LU0561508036.HKD","KURE","IE00B543WZ88.USD","LU1961090484.USD","BK1574","LU0417516902.SGD","LU2488822045.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU0348825331.USD","LU2399975544.HKD","BK1161","LU2778985437.USD","LU0417516571.SGD","LU0417516738.SGD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664828744","title":"We Might See A Profit From Venus Medtech (Hangzhou) Inc. (HKG:2500) Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2664828744","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664828744?lang=en_us&edition=fundamental","pubTime":"2026-09-03 06:19","pubTimestamp":1788387559,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse Venus Medtech (Hangzhou) Inc.'s ( HKG:2500 ) business as it appears the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-2500/venus-medtech-hangzhou-shares/news/we-might-see-a-profit-from-venus-medtech-hangzhou-inc-hkg250","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-2500/venus-medtech-hangzhou-shares/news/we-might-see-a-profit-from-venus-medtech-hangzhou-inc-hkg250","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02500","BK1574","BK1100","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841457","title":"Akeso Says Ivonescimab Meets Overall Survival Endpoint in Phase III HARMONi-2 Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841457","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841457?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:01","pubTimestamp":1788382889,"startTime":"0","endTime":"0","summary":"Akeso says ivonescimab meets overall survival endpoint in Phase III HARMONi-2 lung cancer trialAkeso reported its Phase III HARMONi-2 trial met a key overall survival endpoint in an interim analysis v","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL9yKX9v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU0540923850.HKD","LU0348767384.USD","LU1961090484.USD","IE00B543WZ88.USD","LU0348784397.USD","LU2476274720.SGD","BK1161","LU0417516738.SGD","LU2778985437.USD","LU0417516571.SGD","LU2476274308.USD","LU0348735423.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU2399975544.HKD","LU0348825331.USD","LU0417516902.SGD","09926","IE00BPRC5H50.USD","LU0348766576.USD","LU0634319403.HKD","LU2488822045.USD","LU0561508036.HKD","LU1720050803.USD","BK1574","LU0348827113.USD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664684112","title":"Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line Pd-L1-Positive Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2664684112","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664684112?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:00","pubTimestamp":1788382834,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U140:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348784397.USD","LU2476274720.SGD","LU0348825331.USD","IE00B5MMRT66.SGD","LU0348827113.USD","LU1720050803.USD","BK1161","LU0634319403.HKD","IE00B543WZ88.USD","LU0540923850.HKD","LU0348735423.USD","LU2778985437.USD","LU0417516571.SGD","LU0417516902.SGD","BK1574","LU2399975544.HKD","09926","LU1961090484.USD","LU1794554557.SGD","LU0348767384.USD","LU0417516738.SGD","LU2476274308.USD","IE00BPRC5H50.USD","KURE","LU2488822045.USD","LU0561508036.HKD","LU0348766576.USD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664125841","title":"Akeso - Ivonescimab Demonstrates Statistically Significant Improvement over Pembrolizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2664125841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664125841?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:00","pubTimestamp":1788382834,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U140:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1961090484.USD","IE00BPRC5H50.USD","BK1161","LU2476274720.SGD","LU0348766576.USD","LU0417516902.SGD","LU2778985437.USD","IE00B5MMRT66.SGD","LU0634319403.HKD","IE00B543WZ88.USD","LU0348783233.USD","LU2476274308.USD","BK1574","LU1720050803.USD","LU0348767384.USD","LU2488822045.USD","LU0561508036.HKD","LU0348827113.USD","LU0348735423.USD","09926","LU0540923850.HKD","LU0348784397.USD","LU1794554557.SGD","LU0417516738.SGD","KURE","LU0348825331.USD","LU2399975544.HKD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181297414","title":"HBM Holdings Clarifies Reasons Behind Executive Director's Departure","url":"https://stock-news.laohu8.com/highlight/detail?id=1181297414","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181297414?lang=en_us&edition=fundamental","pubTime":"2026-09-02 22:41","pubTimestamp":1788360072,"startTime":"0","endTime":"0","summary":"On September 2nd, HBM Holdings-B issued a supplementary announcement to provide further details on the changes to its directors and authorized representatives that were disclosed on August 27th. The...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664817416","title":"Alphamab Oncology Files HKEX Next-Day Disclosure Return for Share Buyback at HKD 8.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817416","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664817416?lang=en_us&edition=fundamental","pubTime":"2026-09-02 22:27","pubTimestamp":1788359260,"startTime":"0","endTime":"0","summary":"Alphamab Oncology files HKEX next-day disclosure return for share buyback at HKD 8.57Alphamab Oncology repurchased 115,000 shares on Sept. 2, holding them as treasury shares; no shares were cancelled.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL3rSzX6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198828841","title":"CanSino Biologics' Global Revenue Soars 4,724% in First Half, Systemic Expansion Strategy Unlocks Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1198828841","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198828841?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:10","pubTimestamp":1788354651,"startTime":"0","endTime":"0","summary":"CanSino Biologics Inc. has released its interim report for the first half of 2026, revealing total revenue of RMB 550 million, a 43.81% increase year-on-year, alongside a significant narrowing of its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","BK1515","BK1161","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664478814","title":"Keymed Biosciences Licenses Stapokibart Marketing, Sales Rights in 18 Southeast and Central Asia Markets to Aeira","url":"https://stock-news.laohu8.com/highlight/detail?id=2664478814","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664478814?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354268,"startTime":"0","endTime":"0","summary":"Keymed Biosciences licenses Stapokibart marketing, sales rights in 18 Southeast and Central Asia markets to AeiraKeymed entered an exclusive licensing deal with Aeira to register and commercialize Sta","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL7LCJLF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1583","BK1587","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664814417","title":"KeyMed Biosciences - Aeira Responsible for Registration and Commercialization of Stapokibart Injection in 18 Countries and Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664814417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664814417?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T1AZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","BK1574","BK1583","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664144128","title":"KeyMed Biosciences - Enters Exclusive Licensing Agreement with Aeira Pte for Stapokibart Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2664144128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664144128?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T1AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1587","BK1574","02162","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126045427","title":"OCUMENSION-B Completes Patient Enrollment in Phase III Trial of Dry Eye Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1126045427","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126045427?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:16","pubTimestamp":1788351373,"startTime":"0","endTime":"0","summary":"OCUMENSION-B (01477) has announced the completion of patient enrollment for its Phase III clinical trial of OT-211 (TRYPTYR® acotiamide eye drops) in the People's Republic of China, with a total of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IBBJ","PSYK","BK1191","IBBQ","BK1574","01477","MDTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":7,"totalSize":255,"code":"91000000","status":"200"}]}}